Dna (recombinant Vaccinia Virus Strain Livp Clone Gl-onc1)
Dna (recombinant Vaccinia Virus Strain Livp Clone Gl-onc1) Uses, Dosage, Side Effects, Food Interaction and all others data.
Dna (recombinant Vaccinia Virus Strain Livp Clone Gl-onc1) is under investigation in clinical trial NCT01443260 (A Study of GL-ONC1, an Oncolytic Vaccinia Virus, in Patients With Advanced Peritoneal Carcinomatosis).
Trade Name | Dna (recombinant Vaccinia Virus Strain Livp Clone Gl-onc1) |
Generic | Olvimulogene nanivacirepvec |
Olvimulogene nanivacirepvec Other Names | Dna (recombinant vaccinia virus strain livp clone gl-onc1), DNA (synthetic vaccinia virus oncolytic-strain GLV-1h68 (complete genome)), Olvimulogene nanivacirepvec |
Type | |
Groups | Investigational |
Therapeutic Class | |
Manufacturer | |
Available Country | |
Last Updated: | September 19, 2023 at 7:00 am |
Innovators Monograph
You find simplified version here Dna (recombinant Vaccinia Virus Strain Livp Clone Gl-onc1)